Reference:EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 11 d): Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 5: | Line 5: | ||
d) | d) | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00295-Rem-erp ++ TAG-00065-Sou-nüb ++ TAG-00138-Rem-oni ++ TAG-00329-Saf-lne ++ TAG-00025-Sub-mer | ||
| | |RefModule=4 | ||
| | |RefUnit=4.3.4 | ||
}} | }} | ||
| Line 15: | Line 15: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 4 — Unit 4.3.4 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 32: | Line 35: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00295-Rem-erp|Remote SDV]], [[Glossary:TAG-00065-Sou-nüb|Source data verification]], [[Glossary:TAG-00138-Rem-oni|Remote monitoring]], [[Glossary:TAG-00329-Saf-lne|Safety]], [[Glossary:TAG-00025-Sub-mer|Trial participant]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | EU GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC v5 10-Feb-2022 |
| Validity area | EU |
| Scope(s) | G |
| Document name | GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS
DURING THE COVID-19 (CORONAVIRUS) PANDEMIC |
| Version / Revision | v5
10-Feb-2022 |
| Status | Current |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS DURING THE COVID-19 (CORONAVIRUS) PANDEMIC |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 — Unit 4.3.4 |
| Scope | G |
| Document part | 11
d) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Remote SDV, Source data verification, Remote monitoring, Safety, Trial participant |
| Comment | Created to be valid during COVID-19 pandemic. |
Content
d) Remote source data verification […] Remote SDV may be considered for trials: - involving COVID-19 treatment or prevention; - investigating serious or life-threatening conditions; - where the absence of SDV for critical data may likely pose unacceptable risks toparticipants’ safety or the reliability/integrity of trial results; - involving particularly vulnerable participants such as children or thosetemporarily (e.g. trials in emergency situations) or permanently (e.g. trials in patients with advanced dementia) incapable of giving their informed consent or - in pivotal trials. [...] In the case of these trials, principal investigators should make their own determination as to whether or not the situation at their clinical site allows any of the following options for remote SDV: - Sharing pseudonymised copies of trial related source documents with the monitor; this may be done electronically where manageable by the site staff; - Direct, suitably controlled remote access to trial participants’ electronic medical records; - Video review of medical records with clinical site team support, without sending any copy to the monitor and without the monitor recording images during the review. [...] Remote SDV can be carried out only in agreement with the investigators who should not be put under undue pressure to accept remote SDV and should always give priority to the care to be given to trial participants and other patients. Remote SDV should not be carried out if adequate data protection, including data security and protection of personal data even if pseudonymised, is not ensured. Refer to Annex 1 for controls that, where applicable, can protect trial participants’ rights while permitting remote SDV.
